Table 1.
Comparison of baseline demographic and disease characteristics of AMP-516 ITT population to the target and non-target subsets.
Table 2.
Comparison of change from baseline in mean ETT duration at Week 40 for ITT population vs. target and non-target subsets.
Fig 1.
ME/CFS patients with a ≥25% increase in treadmill ET from baseline at Week 40.
Table 3.
Comparison of change from baseline in mean ETT vertical rise* (feet) at Week 40 for ITT population vs. the target and non-target subsets.
Fig 2.
The Placebo-adjusted percent intra-group mean exercise improvements for rintatolimod: ITT population and the target subset comparisons to drugs approved for non-ME/CFS severe exertional fatigue.
Fig 3.
Rintatolimod-treated patients by ETT response (≥25% vs. <25%): Comparison of change from baseline in vertical rise at Week 40 for the ITT population vs. each subset.